WASHINGTON — Eli Lilly plans to spend $27 billion to build four new drug manufacturing sites in the United States, the company announced Wednesday, at a time when the Trump administration is seeking to persuade drugmakers and other companies to move more of their operations stateside.
The announcement, made during a press conference in Washington, comes as the administration is preparing international tariffs on pharmaceuticals as a way to pressure companies to invest more in the United States instead of overseas. The scope and timing of any tariffs remains unclear though President Trump is said to have encouraged drugmakers to move swiftly.
Three of Lilly’s new U.S. facilities will focus on making active pharmaceutical ingredients, and the fourth will focus on injectable therapies. Lilly said the sites may require 10,000 construction jobs and 3,000 technical jobs. The company also touted its previous $23 billion investment in domestic manufacturing over the past four years, including the creation of new sites in North Carolina, Indiana, and Wisconsin.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.
Already have an account? Log in